Novavax Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Direxion Daily TSLA Bull 2X Shares trades at $9.77. The key difference: Novavax Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| NVAX | TSLL | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $11.19 | $23.03 |
52-Week Low | $6.22 | $6.74 |
Enterprise Value | $1.26B | — |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $9.87, up 7.87% on strong Tesla momentum ahead of the Cybercab event. The technical outlook is bullish with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights investor enthusiasm for leveraged Tesla exposure, though the ETF's structure amplifies volatility risks.
The outlook remains driven by Tesla's performance, with potential upside from product launches but significant risk from daily rebalancing effects. Investors face amplified gains or losses relative to Tesla, requiring careful risk management given the ETF's leveraged structure and Tesla's inherent stock volatility.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →